At the crossroads: Car-T cell therapies shifting gears in AML treatment

Sanjna Sandeep Background: Acute Myeloid Leukemia (AML) is a cancer of the stem cell precursors for hematopoietic cells, causing over 80,000 deaths yearly with a 30.5% 5-year survival rate in the US1. Highly varied gene alterations drive AML’s progression, leading to life-threatening cytopenias1. The “3+7” chemotherapy regimen is the standard…
Cancer Engineering Medicine Featured Abstracts Immunology

Role of KDM6A Mutation in promotion of Bladder Cancer

Dung Dao Background: Bladder cancer, primarily affecting the urothelial cell layer, can be divided into two types: non-muscle invasive (NMIBC) and muscle-invasive (MIBC).1 It is the 4th most common malignancy in males and 11th in females, with about 550,000 new cases, and a high frequency of recurrence.1,2,3 Risk factors include…
Cancer Featured Abstracts